Edition:
India

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

9.88EUR
5:00pm IST
Change (% chg)

€0.25 (+2.65%)
Prev Close
€9.62
Open
€9.68
Day's High
€9.88
Day's Low
€9.65
Volume
205,539
Avg. Vol
406,434
52-wk High
€18.50
52-wk Low
€8.80

Summary

Name Age Since Current Position

Jorge Gallardo Ballart

2011 Chairman of the Board

Peter Guenter

57 2017 Chief Executive Officer, Executive Director

Thomas McKillop

77 2019 Independent Vice Chairman of the Board

Michael McClellan

2019 Chief Financial Officer, Executive Vice President - Finance

Bhushan Hardas

2017 Executive Vice-president R&D and Chief Scientific Officer

Alfredo Baron de Juan

2016 Executive Vice President - Global Commercial Operations

Amita Kent

2019 Senior Vice President Legal, Global Chief Compliance & Data Privacy Officer

Esteve Conesa

2018 Senior Vice President of Human Resources

Eloi Crespo Cervera

2018 Senior Vice President Industrial Operations

Joan Figueras Carreras

Vice Secretary (non-member) General Counsel

Volker Koscielny

2019 Chief Medical Officer

Francesca Wuttke

2019 Chief Digital Officer

Jose Juan Pinto Sala

2016 Non-Member Secretary of the Board

Carlos Gallardo Pique

2014 Director

Antonio Gallardo Torrededia

2014 Director

Enrique De Leyva Perez

2019 Independent Director

Karin Dorrepaal

59 2013 Independent Director

Georgia Garinois-Melenikiotou

2016 Independent Director

Gerhard Mayr

73 2012 Independent Director

Seth Orlow

2016 Independent Director

Biographies

Name Description

Jorge Gallardo Ballart

Mr. Jorge Gallardo Ballart serves as a Chairman of the Board of Directors of Almirall, S.A. Previously, he acted as Chief Executive Officer of the Company until March 17, 2011, and was Executive Member of the Company's Board until July 1, 2011. He joined the Company on November 1, 1965, and has been on the Company's Board since June 30, 1997. He is also Member of the Company's Nominating and Remuneration Committee. He has served as Administrator of Almirall, BV, Almirall AG, Chemol SA, Expharm SA and Almirall SA in Chile, as well as President of GdS SAS. Currently, he acts as Chairman of the Board of Directors of Grupo Plafin SA UNIP. He holds a degree in Industrial Engineering from Universidad Politecnica de Madrid. Holds PhD in Industrial Engineering. — Institutional positions at the EFPIA and Farmaindustria over several periods. — Member of Spain’s Royal Academy of Pharmacy and awarded the President Macià Medal for services rendered.

Peter Guenter

Mr. Peter Guenter serves as the Chief Executive Officer, Executive Director of Almirall, S.A. since October 1, 2017. Prior to that, he was Executive Vice President, General Medicines and Emerging Markets, Member of the Executive Committee and the Global Leadership Team from mid-2015 and Executive Vice President in charge of Global Commercial Operations and Member of the Executive Committee and the Global Leadership Team of the Company from July 1, 2013. He holds a Masters Degree in Physical Education at the Faculty of Medicine and Health Sciences, University of Ghent, Belgium. He started his career in Sales at SmithKline in 1986. He joined the Group in 1995 and held various positions in France, Europe and Global Marketing. In 2000, he was appointed General Manager Belgium and then Vice President for Eastern Europe, Northern Europe & Scandinavia. In 2008, he was appointed General Manager, Commercial Operations for Germany, and in 2011, he was General Manager for the Multi-Country- Organization for Germany, Switzerland and Austria.

Thomas McKillop

Mr. Thomas Fulton Wilson McKillop serves as Independent Vice Chairman of the Board of the Company. since May 29, 2007. Sir Tom McKillop began his career at ICI where he held various positions before being appointed Technical Director. In 1992 he was appointed deputy CEO and in 1994 he became CEO of Zeneca Pharmaceuticals, leading the merger of Astra and Zeneca in 1999, and becoming CEO of AstraZeneca plc until retiring at the end of 2005. Until 2009, he was the Chairman of the Royal Bank of Scotland and a Non-Executive Director of BP. He has been Chairman or non-executive director of various other healthcare companies and received numerous academic awards and honorary degrees.

Michael McClellan

Mr. Michael James McClellan serves as Chief Financial Officer, Executive Vice President - Finance of the Company. Mr. McClellan holds Bachelor degrees in Accounting and Economics from the University of Missouri. He is an experienced financial executive and has leveraged his skills to drive strong business and financial performance in roles of increasing scope, responsibility and geographic reach mainly in the Pharmaceutical industry. Before joining Almirall in 2019, he was most recently CFO of Teva Pharmaceuticals and had also spent many years with Sanofi after starting his career in public accounting.

Bhushan Hardas

Dr. Bhushan Hardas serves as Executive Vice-president R&D and Chief Scientific Officer of the Company. since April 1, 2017. His last position before joining Almirall, he has been the Global Head of R & D Dermatology and Medical Aesthetics and Chief Medical Officer (Devices) in Allergan, located in Irvine, California. He holds a Masters of Business Administration degree.

Alfredo Baron de Juan

Amita Kent

Ms. Amita Kent serves as Senior Vice President Legal, Global Chief Compliance & Data Privacy Officer of the Company. Ms. Kent holds a Bachelor of Science in Biology and Physics (BSc) from the Dalhousie University and a Bachelor of Laws (LLB) from the University of Windsor in Canada. She has over 30 years of experience working in pharmaceutical companies, with expertise in global marketing strategies, business development, compliance, data privacy, FCPA, litigation, regulatory and competition matters. Before joining Almirall, she held VP positions in companies including Merck, Pfizer, Schering-Plough, Pharmacia and Novopharm.

Esteve Conesa

Mr. Esteve Conesa serves as Senior Vice President of Human Resources of the Company. Mr. Conesa holds a Degree in Psychology from the Universitat de Barcelona. He joined Almirall in 2002 as Project Leader HR Organizational Development, and since then he held several positions in the company including HR Business Partner Industrial Operations, Head of Corporate Recruitment and Development, People & Organizational Development Director and Chief HR Officer US Operations until in 2018 when becoming Senior Vice-president Human Resources.

Eloi Crespo Cervera

Mr. Eloi Crespo Cervera serves as Senior Vice President Industrial Operations of the Company. Mr. Crespo holds a Degree in Organic Chemistry from the Universitat de Barcelona, and an Interuniversitary Master of Business Administration (MBA) from the Universitat de Barcelona, Universitat Autònoma de Barcelona and Universitat Politècnica de Catalunya. He joined Almirall in 1997 in Purchasing, where he held different positions as Purchaser, Manager, and Director; in 2010 he med and assumed responsibility in a new area to become Industrial Director and since 2018 is Senior VP Industrial Operations..

Joan Figueras Carreras

Mr. Joan Figueras Carreras serves as Vice Secretary (non-member) General Counsel of the Company. He joined the Company on October 1, 1991. Mr. Figueras holds a Bachelor’s Degree in Laws from the Universitat de Barcelona and joined Almirall in 1993 as Senior Director of Legal Department, working in that position until 2013. Since then he is General Counsel of the company and Vice-Secretary of the Board of Directors. From 2007 he also acts as Secretary of the Management Board.

Volker Koscielny

Dr. Volker Koscielny serves as Chief Medical Officer of the Company. Dr. Koscielny is Medical Doctor from the Freie Universitaet Berlin and holds a Business and Managerial Economics MBA from the University of Durham. He has a solid clinical, academic and scientific background, experience managing large teams and a results-oriented mentality. Before joining Almirall he held different positions in companies like Celgene, GlaxoSmithKline, Pfizer, Servier or Boehringer Ingelheim. As a member of the Management Board, he leads the Medical Affairs and Medical Innovation strategy, providing guidance and a strong medical perspective as a partner to the R&D and commercial teams.

Francesca Wuttke

Dr. Francesca Domenech Wuttke Ph.D. serves as Chief Digital Officer of the Company. Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences. Dr. Wuttke brings with her broad drug development and healthcare expertise, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC., and worked at Novartis where she managed the strategy and commercialization for the existing portfolio of cell therapy assets. Since 2019 she is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end company-wide digital transformation.

Jose Juan Pinto Sala

Carlos Gallardo Pique

Mr. Carlos Gallardo Pique serves as a Director of Almirall, S.A. since August 28, 2014. Mr. Carlos Gallardo holds a Degree in Industrial Engineering from the Polytechnic University of Catalonia and MBA from Stanford University (US). With extensive experience in the pharmaceutical sector, he has held management positions at Pfizer and Almirall, mainly in the areas of Licensing, Business Development and Country Management. He was General Manager of Almirall's subsidiary in the UK and Ireland. Previously, he worked in the automotive sector as an expert and manager of industrial organisation. In 2014 Mr. Carlos Gallardo founded CG Health Ventures where he serves as the Managing Director. CG Health Ventures builds digital health companies and invests in early stage health technology companies globally.

Antonio Gallardo Torrededia

Mr. Antonio Gallardo Torrededia serves as Director of Almirall, S.A. Mr. Antonio Gallardo holds a degree in Business Science from the University of Barcelona and an Executive MBA from the University of Chicago. He also has a Master's degree in Marketing from ESADE. He developed his first professional stage in Akzo Nobel during 7 years, reaching the position of Marketing Director, and in 1999 he joined Almirall as area manager. Later he was Director of Pharmacy Marketing, after which he joined the medical visit network as Area Manager and later as Division Chief In 2008 he left Almirall to continue in the family business, where he took charge of the real estate area.

Enrique De Leyva Perez

Mr. Enrique De Leyva Perez serves as Independent Director of the Company. Mr. De Leyva holds a Degree in Civil Engineering from the Engineering School of Madrid and an MBA from Columbia Business School, where he was a Fulbright Scholar and specialised in Finance and Accounting. He has developed his career in top-level companies such as Unión Fenosa and McKinsey & Company in various executive positions and countries (including the UK and USA), and is currently one of the founding partners of Magnum Industrial Partners, a leading Iberian private equity firm. He also belongs to the Boards of Directors of Indra as well as several portfolio companies of the Magnum funds.

Karin Dorrepaal

Dr. Karin Louise Dorrepaal Ph.D. serves as Independent Director of the Company. Mrs. Dorrepaal has a PhD from the Free University of Amsterdam, and holds an MBA from the Rotterdam School of Management. In 1990 she joined Booz Allen Hamilton, Management Consultants, where she remained until 2004, being appointed Vice President (partner) in 2000. She specializes in the pharmaceutical industry and has advised large companies on strategy, sales, marketing and supply chain issues. In 2004 she was appointed to the Board of Executive Directors of Schering AG. Following the acquisition of this company by Bayer AG, Ms. Dorrepaal left her position. Currently she is on the Board of Directors of Gerresheimer AG, Paion AG, the Kerry Group plc. And several non-listed companies.

Georgia Garinois-Melenikiotou

Ms. Georgia Garinois-Melenikiotou has been appointed as Independent Director of the Company. Mrs. Garinois-Melenikiotou holds a Degree in Mechanical Engineering from the National Technical University of Athens, and Master's in Management from the Massachusetts Institute of Technology. She is the Execitive Vice President of Corporate Marketing at the Estée Lauder Companies, Inc., and Board Member of the MIT Sloan School of Management and Operating Partner at Talomon Capital LTD. Before joining Estée Lauder in 2010. Ms Garinois-Melenikiotou held various management positions up to Global President at Johnson & Johnson, where she remained for 27 years and worked in seven countries.

Gerhard Mayr

Mr. Gerhard N. Mayr serves as an Independent Director of Almirall, S.A. since October 19, 2012. He acts as a Member of Company's Nominating and Remuneration Commitee. He was Member of the Audit Commitee of the Company. He is also Member of the Board of Directors of UCB SA. He holds a Masters of Business Administration degree from the Stanford University (1972) and a Master's degree in Chemical Engineering from Eidgenoessische Technische Hochschule Zuerich (1969). — Degree in Chemical Engineering and MBA. — Has held positions in several companies in the pharmaceutical sector. — President and member of the board of directors of several companies.

Seth Orlow

Mr. Seth J. Orlow has been appointed as Independent Director of the Company. Dr. Orlow holds a Bachelor of Medicine and PhD in Molecular Pharmacology from the Albert Einstein College of Medicine of Yeshiva University (USA) and a Bachelor of Science in Biomedical Sciences from Harvard College (USA). He has been Senior consultant to Pharus Advisors, Chairman and Professor of Dermatology at New York University School of Medicine and Member of the Advisory Board of Provectus Pharmaceuticals, Inc. In the past, Dr. Orlow was, among others, a partner at Easton Capital Partners, co-founder of Anaderm Research Corporation, and a director of Protez Pharmaceuticals and Transave. He also belongs to the Board of Directors of R2 Technologies, Inc.